Fresenius Medical Care AG (NYSE:FMS) Stake Lifted by Ethic Inc.

Ethic Inc. increased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 25.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,286 shares of the company’s stock after purchasing an additional 9,856 shares during the period. Ethic Inc.’s holdings in Fresenius Medical Care were worth $1,116,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in FMS. Northern Trust Corp increased its position in shares of Fresenius Medical Care by 45.9% during the 4th quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock valued at $8,200,000 after purchasing an additional 113,953 shares during the period. Moran Wealth Management LLC boosted its stake in Fresenius Medical Care by 9.1% during the fourth quarter. Moran Wealth Management LLC now owns 254,710 shares of the company’s stock valued at $5,767,000 after buying an additional 21,334 shares in the last quarter. ABC Arbitrage SA bought a new position in Fresenius Medical Care during the fourth quarter valued at about $4,215,000. OLD Mission Capital LLC acquired a new position in Fresenius Medical Care during the fourth quarter worth about $3,545,000. Finally, Broyhill Asset Management bought a new stake in Fresenius Medical Care in the fourth quarter worth about $3,412,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Performance

Shares of NYSE FMS opened at $27.99 on Wednesday. The stock’s fifty day simple moving average is $24.73 and its 200 day simple moving average is $23.53. The stock has a market capitalization of $16.43 billion, a price-to-earnings ratio of 23.13, a PEG ratio of 0.76 and a beta of 0.85. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $28.59.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. As a group, sell-side analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The company also recently announced an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be given a $0.7871 dividend. This is an increase from Fresenius Medical Care’s previous annual dividend of $0.44. This represents a dividend yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care’s dividend payout ratio (DPR) is 49.11%.

Wall Street Analyst Weigh In

FMS has been the subject of several research reports. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial increased their target price on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Monday.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.